Technical Analysis for DRNA - Dicerna Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 13.33 1.76% 0.23
DRNA closed up 1.76 percent on Tuesday, March 19, 2019, on 66 percent of normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical DRNA trend table...

Date Alert Name Type % Chg
Mar 19 200 DMA Support Bullish 0.00%
Mar 19 Spinning Top Other 0.00%
Mar 19 Inside Day Range Contraction 0.00%
Mar 19 Wide Bands Range Expansion 0.00%
Mar 19 Overbought Stochastic Strength 0.00%
Mar 19 Up 3 Days in a Row Strength 0.00%
Mar 19 Up 4 Days in a Row Strength 0.00%
Mar 19 Up 5 Days in a Row Strength 0.00%
Mar 18 Shooting Star Candlestick Bearish 1.76%
Mar 18 Crossed Above 200 DMA Bullish 1.76%

Older signals for DRNA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for liver diseases and cancers based on a proprietary RNA interference technology platform in the United States and internationally. The company's development programs include DCR-PH1 for the treatment of primary hyperoxaluria 1 (PH1) through targeting the liver metabolic enzyme glycolate oxidase; and other rare inherited diseases involving disease target genes expressed in the liver, including maple syrup urine disease, familial amyloid polyneuropathy or cardiomyopathy, alpha-1 anti-trypsin hepatocyte inclusions, hemophilia A and B, paroxysmal nocturnal hemoglobinuria, and others. It is also developing DCR-M1711 for the treatment of various cancers through targeting the MYC oncogene, a gene that causes or promotes cancer when abnormally expressed or activated; and a product candidate targeting the oncogene KRAS. The company has a research collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd. for the research, development, and commercialization of DsiRNA molecules and drug delivery technologies for therapeutic targets in oncology; and a license agreement with City of Hope, an academic research and medical center, to manufacture, use, offer for sale, sell, and import products related to DsiRNA for the prevention and treatment of various diseases in humans. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Watertown, Massachusetts.
Medicine Biopharmaceutical Cancer Diseases Alpha Disease Cancers Enzymes Paroxysmal Nocturnal Hemoglobinuria Carcinogenesis Drug Delivery Technologies Hemophilia A Liver Liver Diseases Ras Subfamily Cardiomyopathy C Met Familial Amyloid Polyneuropathy Hyperoxaluria Primary Hyperoxaluria Treatment Of Various Cancers Treatment Of Various Diseases
Is DRNA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 17.98
52 Week Low 8.71
Average Volume 556,362
200-Day Moving Average 13.0496
50-Day Moving Average 11.1243
20-Day Moving Average 11.849
10-Day Moving Average 12.049
Average True Range 0.7286
ADX 24.0
+DI 32.9585
-DI 14.6015
Chandelier Exit (Long, 3 ATRs ) 11.3442
Chandelier Exit (Short, 3 ATRs ) 12.3358
Upper Bollinger Band 13.6731
Lower Bollinger Band 10.0249
Percent B (%b) 0.91
BandWidth 30.789096
MACD Line 0.4785
MACD Signal Line 0.3381
MACD Histogram 0.1404
Fundamentals Value
Market Cap 277.86 Million
Num Shares 20.8 Million
EPS -3.20
Price-to-Earnings (P/E) Ratio -4.17
Price-to-Sales 155.10
Price-to-Book 7.93
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.19
Resistance 3 (R3) 14.15 13.84 14.04
Resistance 2 (R2) 13.84 13.62 13.85 13.99
Resistance 1 (R1) 13.58 13.48 13.71 13.62 13.95
Pivot Point 13.27 13.27 13.33 13.28 13.27
Support 1 (S1) 13.01 13.05 13.14 13.05 12.71
Support 2 (S2) 12.70 12.91 12.71 12.67
Support 3 (S3) 12.44 12.70 12.62
Support 4 (S4) 12.48